Table 4.

Summary of fitted univariate Cox proportional hazards models for OS and progression-free survival (PFS)

OSPFS
nHRLow 95%High 95%PHRLow 95%High 95%P
Race (w vs. not-w)1141.0660.5142.2110.8630.9730.4901.9350.939
Mets.at.diagnosis1141.6861.0752.6430.0231.5241.0122.2960.044
log.T.diag1140.8420.7340.9650.0140.8320.7290.9500.007
No. of criteria = C1+….+C71141.4101.1261.7660.0031.2110.9701.5110.092
C11141.5640.9812.4930.0601.3540.8602.1310.191
C21141.0880.6411.8460.7551.0960.6511.8460.730
C31141·2300.6932.1820.4791.3620.7862.3620.271
C41131.6821.0982.5750.0171.6771.1322.4850.010
C51141.0130.6161.6660.9600.7100.4381.1480.163
C61082.1501.2353.7410.0071.1260.6731.8820.651
LDH > 5461142.8341.8374.375<0.00012.4721.6453.714<0.0001
CEA > 61143.2411.9735.325<0.00011.4000.8892.2050.150
IHC (+ vs. –)521.2290.6752.2380.5000.9190.5151.6410.780
C71140.7960.5251.2060.2810.8590.5811.2700.446
GS ≥ 81011.2030.7301.9840.4701.3930.8642.2440.170
PS = 025Ref.Ref.
PS = 1742.3961.3164.3630.0041.9041.1493.1540.012
PS = 2153.9851.8188.7330.0013.0031.5135.9610.002
Age1141.0030.9771.0290.8220.9940.9731.0160.618
log.ACTH1011.1340.7741.6620.5171.1210.7751.6210.545
log.ADH741.1590.9301.4440.1901.0940.8721.3720.436
log.Alk1041.2490.9531.6360.1070.8960.6811.1780.431
log.BS.Alk1081.2921.0401.6050.0211.0020.8151.2330.983
log.Calcitonin881.5811.2022.0790.0011.5661.1962.0500.001
Calcium1130.6830.4391.0640.0921.0390.6941.5570.851
log.CEA1131.5231.3251.752<0.00011.2631.0831.4740.003
log.ChrA-1740.8710.7021.0790.2060.9410.7691.1510.553
log.ChrA-2a351.6301.0102.6100.0451.2000.8031.7890.375
log.GRP570.7910.5011.2470.3130.7940.5371.1730.247
Hb1140.8040.7090.9120.0010.9150.8171.0250.127
log.LDH1142.7141.6984.340<0.00012.5701.6933.9010.0001
log.PAP1111.0800.9521.2260.2311.0840.9561.2290.211
log.PSA1141.0290.9131.1610.6391.0310.9211.1550.591
PSA DT521.0660.9351.2160.3401.0120.9161.1180.810
log.Somat1062.2531.3203.8450.0031.7631.0722.8990.025
log.uNTX611.4040.9702.0310.0720.9860.6991.3920.936

Abbreviations: ACTH, adrenocorticotropic hormone; ADH, antidiuretic hormone; Alk, alkaline phosphatase; BS, bone-specific; C1–C7, eligibility criteria 1–7; ChrA-1, serum chromogranin A measured by Calbiotech chemiluminescence ELISA at Quest Diagnostics; ChrA-2, serum chromogranin A measured by homogeneous time-resolved fluorescence conducted at Mayo Medical Laboratories; DT, doubling time; GRP, gastrin-releasing peptide; GS, Gleason score; Hb, hemoglobin; IHC, immunohistochemistry; Mets, metastases; PS, performance status; Somat, somatostatin; T.diag., time from diagnosis; uNTX, urine N-telopeptides; w, white.

  • aDuring the study, the method for measuring serum chromogranin A was changed in the MD Anderson laboratory from Calbiotech chemiluminescence ELISA at Quest Diagnostics to homogeneous time-resolved fluorescence conducted at Mayo Medical Laboratories.